We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




‘Smart' Molecules Devised for Breast, Ovarian Cancer Therapies

By Biotechdaily staff writers
Posted on 04 Apr 2007
New non-toxic and targeted therapies for metastatic breast and ovarian cancers may now be possible because researchers have found that a protein called podocalyxin, which had previously been shown to be a predictor of metastatic breast cancer, changes the shape and adhesive quality of tumor cells, affecting their ability to grow and metastasize. More...


In a collaboration between stem cell and cancer scientists from the University of British Columbia (UBC; Vancouver, Canada), their discovery demonstrated that the protein not only predicted the spread of breast cancer cells, it likely helped to cause it. The study's results were published online in March 2007 by the Public Library of Science.

"We believe we've found a new important culprit in metastatic breast cancer, which opens up an entirely new avenue of cancer research,” stated Dr. Calvin Roskelley, an associate professor of cellular and physiological science who specializes in breast cancer and is co-senior principal investigator. "The culprit is hiding in plain sight on the surface of tumor cells, so we are now developing ‘smart' molecules to block its function. The ultimate goal is to generate new targeted, non-toxic treatments--very different from the standard ‘slash and burn' chemotherapy.”

The researchers found that podocalyxin considerably expands the non-adhesive face of cells, allowing individual cells to push aside adhesion molecules located between tumor cells. The "freed” cells then move away from the original site to form new tumors at other sites. Furthermore, the protein causes tumor cells to grow microvilli, or hair-like projections, that may help propel cancer cells to other sites.

Moreover, when the protein expands the non-adhesive face of cells, it pulls along with it a second protein called NHERF-1--a protein previously shown to be implicated in cell growth and invasion. The researchers now believe the process applies to difficult-to-treat invasive breast and ovarian tumors.

"We're now tapping into what causes the characteristic cell shape changes seen in cancerous tumors and possibly how these cells grow and metastasize. It gives us a whole new target for therapy,” said associate professor of medical genetics and stem cell expert Dr. Kelly McNagny, co-senior principal investigator. "If we can block the protein, we may be able to stop the spread of cells.”

The next steps of the research will involve advancing the research in animal models, designing antibodies to block the function of the protein, and working with the UBC-based Center for Drug Research and Development to identify new therapies to combat metastasizing cancer.

According to the researchers, data gleaned from this discovery may speed development of new therapies to within 10 years.


Related Links:
University of British Columbia

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.